Gate2Brain

A novel technology platform for the delivery of therapeutics across biological barriers.

#Life_Sciences

Point Circle Elephant

Gate2Brain

Gate2Brain is a Barcelona-based biotech company developing a proprietary peptide-shuttle platform that enables therapies to cross the blood–brain barrier and reach the brain more effectively. Founded as a spin-off from IRB Barcelona, the University of Barcelona, and Sant Joan de Déu Hospital, the company focuses on improving treatment delivery for neurological diseases and pediatric brain cancers. Its lead program, G2B-002, targets aggressive tumors such as DIPG and pediatric glioblastoma and has received Orphan Drug Designation from both the FDA and EMA. Gate2Brain’s technology also has broader applications in CNS disorders and targeted drug delivery.

The Elephants
Involved

Our Role

  • Public Funding
Raised
0 M

Innitius and
Inveniam

Inveniam supported the company in winning an EIC Accelerator grant.

Ready to Take Control of Your Innovation?

We look forward to learning about your innovation.